phrykt

Vaxcyte, Inc. (PCVX): who owns it and who trades it

As of Nov 16, 2026, PCVX insiders reported 60 open-market sales worth $13.8M and no purchases in the last 12 months, with 90% of the sale value made under pre-set 10b5-1 plans. The largest seller was Grant Pickering (CEO), with $3.6M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Vaxcyte

From the latest filings

Overall: about as much buying as selling. Insiders and famous investors mostly sold. Congress mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PCVX

327 funds and institutions reported PCVX shares worth $9.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 14.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)14.4%
Jupiter Topco LLC12.4%
T. Rowe Price Investment Management, Inc.8.5%
BlackRock, Inc.8.4%
Ra Capital Management, L.P.7.9%
Wellington Management Group LLP4.8%
Vanguard Portfolio Management LLC4.6%
Vanguard Capital Management LLC4.4%
State Street Corp3.7%
Deep Track Capital, LP3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)20.85M14.44%$1.2B+26%
Jupiter Topco LLC17.97M12.44%$1B–
T. Rowe Price Investment Management, Inc.12.21M8.45%$710M+1%
BlackRock, Inc.12.07M8.36%$702M+10%
Ra Capital Management, L.P.11.47M7.95%$667MNo change
Wellington Management Group LLP7.00M4.85%$407M+25%
Vanguard Portfolio Management LLC6.59M4.57%$383M+5%
Vanguard Capital Management LLC6.35M4.40%$369M+1%
State Street Corp5.35M3.71%$311M+21%
Deep Track Capital, LP4.30M2.98%$250MNo change
Geode Capital Management, LLC3.46M2.40%$201M+8%
T. Rowe Price Associates2.99M2.07%$174M+206%
Kynam Capital Management, LP2.92M2.02%$170MNo change
Westfield Capital Management Co LP2.47M1.71%$144M-32%
Caligan Partners LP2.19M1.52%$127M+6%
Paradigm Biocapital Advisors LP2.13M1.47%$124M-56%
Bellevue Group AG1.97M1.37%$115M+66%
D. E. Shaw & Co., Inc.1.90M1.32%$111M-34%
Maverick Capital Ltd1.61M1.12%$93.8M+17%
Charles Schwab Investment Management Inc1.46M1.01%$85.1M+4%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PCVX insiders reported $0 of open-market purchases and $13.8M of sales. 90% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$13.8M
60 trades, 5 people
Sales under a 10b5-1 plan
90%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$3.3M$3.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Harpreet S. DhaliwalChief Technical Ops OffiSale plan7,135$67.33$480KForm 4
Nov 11, 2026Harpreet S. DhaliwalChief Technical Ops OffiSale plan9,345$68.16$637KForm 4
Nov 11, 2026Harpreet S. DhaliwalChief Technical Ops OffiSale plan520$68.82$35.8KForm 4
Nov 2, 2026Elvia CowanVice presidentSale plan2,414$60.77$147KForm 4
Nov 2, 2026Elvia CowanVice presidentSale plan586$61.55$36.1KForm 4
Nov 2, 2026Jim WassilVice presidentSale plan1,907$60.78$116KForm 4
Nov 2, 2026Jim WassilVice presidentSale plan343$61.57$21.1KForm 4
Oct 5, 2026Elvia CowanVice presidentSale plan19,000$86.74$1.6MForm 4
Oct 5, 2026Jim WassilVice presidentSale plan18,000$86.74$1.6MForm 4
Oct 1, 2026Jim WassilVice presidentSale plan2,155$56.65$122KForm 4
Oct 1, 2026Jim WassilVice presidentSale plan95$57.09$5.4KForm 4
Sep 9, 2026Jim WassilVice presidentSale1,334$59.52$79.4KForm 4
Sep 4, 2026Jim WassilVice presidentSale1,381$61.16$84.5KForm 4
Sep 1, 2026Jim WassilCHIEF OPERATING OFFICERSale303$61.42$18.6KForm 4
Sep 1, 2026Jim WassilCHIEF OPERATING OFFICERSale1,537$60.89$93.6KForm 4
Sep 1, 2026Jim WassilCHIEF OPERATING OFFICERSale713$61.48$43.8KForm 4
Sep 1, 2026Jim WassilCHIEF OPERATING OFFICERSale924$60.96$56.3KForm 4
Aug 5, 2026Harpreet S. DhaliwalChief Technical Ops OffiSale plan17,000$55.00$935KForm 4
Aug 3, 2026Jim WassilCHIEF OPERATING OFFICERSale plan861$53.50$46.1KForm 4
Aug 3, 2026Jim WassilCHIEF OPERATING OFFICERSale plan1,389$54.09$75.1KForm 4
Aug 3, 2026Andrew GuggenhimeCFOSale plan6,956$53.76$374KForm 4
Aug 3, 2026Andrew GuggenhimeCFOSale plan3,044$54.18$165KForm 4
Jul 27, 2026Grant PickeringCEOSale plan622$55.54$34.5KForm 4
Jul 27, 2026Grant PickeringCEOSale plan244$55.96$13.7KForm 4
Jul 27, 2026Grant PickeringCEOSale plan756$55.52$42KForm 4
Jul 27, 2026Grant PickeringCEOSale plan4,415$55.93$247KForm 4
Jul 27, 2026Grant PickeringCEOSale plan11,783$55.52$654KForm 4
Jul 27, 2026Grant PickeringCEOSale plan378$55.91$21.1KForm 4
Jul 6, 2026Andrew GuggenhimeCFOSale plan2,087$57.76$121KForm 4
Jul 6, 2026Andrew GuggenhimeCFOSale plan7,913$57.16$452KForm 4
Jul 1, 2026Jim WassilCHIEF OPERATING OFFICERSale plan6$57.82$347Form 4
Jul 1, 2026Jim WassilCHIEF OPERATING OFFICERSale plan456$57.47$26.2KForm 4
Jul 1, 2026Jim WassilCHIEF OPERATING OFFICERSale plan1,788$56.03$100KForm 4
Jun 26, 2026Grant PickeringCEOSale plan207$54.22$11.2KForm 4
Jun 26, 2026Grant PickeringCEOSale plan602$55.30$33.3KForm 4
Jun 26, 2026Grant PickeringCEOSale plan191$56.27$10.7KForm 4
Jun 26, 2026Grant PickeringCEOSale plan6,683$54.28$363KForm 4
Jun 26, 2026Grant PickeringCEOSale plan9,137$55.27$505KForm 4
Jun 26, 2026Grant PickeringCEOSale plan6,417$56.12$360KForm 4
Jun 26, 2026Grant PickeringCEOSale plan312$54.35$17KForm 4
Jun 26, 2026Grant PickeringCEOSale plan356$55.23$19.7KForm 4
Jun 26, 2026Grant PickeringCEOSale plan332$55.99$18.6KForm 4
Jun 18, 2026Grant PickeringCEOSale plan22,236$52.50$1.2MForm 4
Jun 18, 2026Grant PickeringCEOSale plan225$52.51$11.8KForm 4
Jun 18, 2026Grant PickeringCEOSale plan1,000$52.50$52.5KForm 4
Jun 18, 2026Andrew GuggenhimeCFOSale plan10,000$53.00$530KForm 4
Jun 1, 2026Jim WassilCHIEF OPERATING OFFICERSale plan1,949$49.40$96.3KForm 4
Jun 1, 2026Jim WassilCHIEF OPERATING OFFICERSale plan301$50.26$15.1KForm 4
May 1, 2026Jim WassilCHIEF OPERATING OFFICERSale plan2,250$56.83$128KForm 4
Apr 7, 2026Elvia CowanVice presidentSale plan3,000$60.00$180KForm 4
Apr 1, 2026Jim WassilCHIEF OPERATING OFFICERSale plan838$58.93$49.4KForm 4
Apr 1, 2026Jim WassilCHIEF OPERATING OFFICERSale plan1,412$58.14$82.1KForm 4
Mar 17, 2026Elvia CowanVice presidentSale plan405$56.26$22.8KForm 4
Mar 17, 2026Elvia CowanVice presidentSale plan1,487$55.39$82.4KForm 4
Mar 11, 2026Elvia CowanVice presidentSale plan2,500$58.59$146KForm 4
Mar 10, 2026Jim WassilCHIEF OPERATING OFFICERSale plan4,968$59.16$294KForm 4
Mar 10, 2026Jim WassilCHIEF OPERATING OFFICERSale plan2,427$58.32$142KForm 4
Dec 31, 2025Harpreet S. DhaliwalChief Technical Ops OffiSale9,743$46.69$455KForm 4
Dec 23, 2025Elvia CowanVice presidentSale6,716$47.94$322KForm 4
Dec 23, 2025Elvia CowanVice presidentSale4,907$47.90$235KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Grant PickeringCHIEF EXECUTIVE OFFICER, Director–$3.6MJul 27, 2026
Jim WassilCHIEF OPERATING OFFICER–$3.3MNov 2, 2026
Elvia CowanSVP, FINANCE–$2.8MNov 2, 2026
Harpreet S. DhaliwalChief Technical Ops Officer–$2.5MNov 11, 2026
Andrew GuggenhimePRESIDENT AND CFO–$1.6MAug 3, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PCVX short interest

High short interest. 10.3% of PCVX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 11%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 15.36M PCVX shares were sold short, 10.3% of the shares outstanding, up 5.0% from the report before. At the average daily volume of 2.28M shares, buying them all back would take about 6.7 trading days (days to cover).

Shares short, % of all shares

10.3%May 15Oct 3012.5%

Days to cover

6.7May 15Oct 3017.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202615.36M10.32%+5%2.28M6.7
Oct 15, 202614.62M9.83%-15%5.05M2.9
Sep 30, 202617.29M11.62%+7%1.52M11.4
Sep 15, 202616.13M10.84%+7%1.24M13.0
Aug 31, 202615.02M10.09%+1%947,05215.9
Aug 14, 202614.80M9.94%+2%933,36815.8
Jul 31, 202614.46M10.02%+2%976,18214.8
Jul 15, 202614.23M9.86%-19%1.15M12.4
Jun 30, 202617.47M12.10%+19%2.53M6.9
Jun 15, 202614.63M10.13%+1%1.36M10.7
May 29, 202614.47M10.02%+5%1.64M8.8
May 15, 202613.79M9.55%-3%1.78M7.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded PCVX

Since Nov 17, 2024, 2 members of Congress reported 6 purchases and 1 sale of PCVX. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Jul 16, 2026, reported Sep 4, 2026.

Purchases 6Sales 1

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Jul 16, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfSep 4, 2026Report
May 13, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJun 8, 2026Report
May 12, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJun 8, 2026Report
Apr 28, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfMay 6, 2025Report
Apr 15, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfMay 6, 2025Report
Apr 14, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfMay 6, 2025Report
Mar 5, 2025Jefferson Shreve (R-IN)Sale$15K–$50KSelfApr 11, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Vaxcyte company events

Vaxcyte filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Oct 9, 2026AgreementVaxcyte, Inc. consummated the sale and issuance of $575 million of its 1.50% Convertible Senior Notes due 2032 to certain underwriters. Filing
  3. Oct 5, 2026AnnouncementThe Company also made available the slide presentation attached as Exhibit 99.2 to this Current Report on Form 8-K, which is incorporated herein by reference. Filing
  4. Sep 3, 2026LeadershipVaxcyte, Inc. appointed David McAvoy as the Company's Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary. Filing
  5. Aug 5, 2026ResultsReleased financial results. Filing
  6. Jul 15, 2026LeadershipHeath Lukatch notified the Board of Directors of Vaxcyte, Inc. of his retirement from the Board, effective as of July 16, 2026. Filing
  7. Jun 23, 2026LeadershipJacks Lee notified the Board of Directors of Vaxcyte, Inc. of his retirement from the Board, effective as of June 17, 2026. Filing
  8. Jun 16, 2026VoteReported shareholder vote results. Filing
  9. May 6, 2026ResultsReleased financial results. Filing
  10. Feb 24, 2026AnnouncementVaxcyte, Inc. entered into a sales agreement with Leerink Partners LLC, pursuant to which the Company may sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $500 million, from time to time through the Placement Agent. Filing
  11. Feb 24, 2026ResultsReleased financial results. Filing
  12. Feb 2, 2026AnnouncementVaxcyte, Inc. entered into an underwriting agreement with BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein, relating to the issuance and sale of 11,000,000 shares of its common stock, par value $0.001… Filing
  13. Dec 19, 2025LeadershipVaxcyte, Inc. amended existing Executive Change in Control and Severance Agreements with (i) Grant Pickering, Chief Executive Officer and member of the Company’s Board of Directors, dated as of June 12, 2020, (ii) Andrew Guggenhime, President and Chief Financial Officer, dated as of June 12, 2020… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Vaxcyte financials

Famous investors that hold PCVX

4 of the 50 well-known investors we track reported holding PCVX in their latest 13F filing. The largest position is Lee Ainslie's, worth $77.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Lee Ainslie · Maverick CapitalQ3 20261.36M$77.4M0.6%-16%
Ken Griffin · Citadel AdvisorsQ3 2026154,204$8.8M0.0%New
Israel Englander · Millennium ManagementQ3 202667,027$3.8M0.0%-51%
Ray Dalio · Bridgewater AssociatesQ3 202640,377$2.3M0.0%-20%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named PCVX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Wellington Management Group LLP13G5.2%
Nov 16, 2026Wellington Management Group LLP13G5.2%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A9.6%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A11.6%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A9.6%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A11.6%

Questions about Vaxcyte, Inc. (PCVX) stock

Who owns the most PCVX stock?

The largest reported owner of Vaxcyte, Inc. (PCVX) is FMR LLC (Fidelity), with 14.4% of the company. In total, 327 funds and institutions reported holding PCVX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are PCVX insiders buying or selling?

In the last 12 months, PCVX insiders reported no open-market purchases and 60 sales worth $13.8M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in PCVX?

As of Oct 30, 2026, 15.36M PCVX shares were sold short, 10.3% of the shares outstanding, up 5.0% from the report before. At the average daily volume of 2.28M shares, buying them all back would take about 6.7 trading days (days to cover). See the history.

Have members of Congress traded PCVX?

Yes. 2 members of Congress reported 6 purchases and 1 sale of PCVX since Nov 17, 2024. The latest was reported on Sep 4, 2026. See the trades.

Which famous investors hold PCVX?

4 of the 50 well-known investors we track reported PCVX in their latest 13F filing, including Lee Ainslie, Ken Griffin, Israel Englander. The largest position is worth $77.4M. See all holders.

Executive pay

Vaxcyte's chief executive was paid a total of $14.5M for the year ended Dec 31, 2025, down 64% from $39.6M the year before. In the last 12 months, Vaxcyte's executives and directors bought no stock on the open market and sold $13.8M.

Chief executive, total pay$14.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$4.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.